Pulmonary Abscess

A pulmonary abscess is a localized, encapsulated collection of pus within the lung parenchyma, resulting from an infectious process that leads to tissue necrosis and liquefaction. It is a severe, often life-threatening condition characterized by a central cavity filled with purulent exudate, surrounded by a fibrous capsule and inflammatory infiltrate. Pulmonary abscesses can be classified as primary (arising from direct pulmonary infection) or secondary (resulting from hematogenous spread, aspiration, or extension from adjacent structures). They may be single or multiple, and can occur in any lung lobe, though the caudal lobes are most commonly affected due to gravitational predisposition. The condition represents a significant diagnostic and therapeutic challenge in veterinary medicine, requiring aggressive medical management and, in some cases, surgical intervention.

The most common causative agents are bacteria, with anaerobic organisms being predominant. Common isolates include Bacteroides spp., Fusobacterium spp., Peptostreptococcus spp., and Prevotella spp. Aerobic bacteria such as Escherichia coli, Pasteurella multocida, Streptococcus spp., Staphylococcus spp., Klebsiella pneumoniae, and Pseudomonas aeruginosa are also frequently involved. In dogs, Bordetella bronchiseptica and Mycoplasma spp. can be primary pathogens. Fungal etiologies include Aspergillus spp., Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum, particularly in endemic regions. Parasitic causes are rare but can include Paragonimus kellicotti (lung fluke) and Dirofilaria immitis (heartworm) with secondary abscessation. Viral infections, such as canine distemper virus or feline calicivirus, can predispose to secondary bacterial abscess formation. The pathogenesis often involves aspiration of oropharyngeal flora, hematogenous seeding from distant sites (e.g., endocarditis, septicemia), or extension from mediastinal or pleural infections. Virulence factors include bacterial toxins, proteases, and capsule formation that evade host defenses and promote tissue destruction.

Pulmonary abscesses are uncommon in dogs and cats but can occur in any age, breed, or sex. There is no strong breed predisposition, but large-breed dogs may be more prone to aspiration pneumonia, a common precursor. Middle-aged to older animals are more frequently affected due to increased risk of comorbidities such as periodontal disease, megaesophagus, or immunosuppression. Geographic variation exists for fungal causes; for example, blastomycosis is more common in the Mississippi River Valley, coccidioidomycosis in the southwestern United States, and histoplasmosis in the Ohio River Valley. Incidence rates are not well documented, but pulmonary abscesses account for a small percentage of respiratory diseases. Immunocompromised animals (e.g., those on corticosteroids, with diabetes mellitus, or with retroviral infections in cats) are at higher risk. Environmental factors such as poor ventilation, overcrowding, and exposure to contaminated soil or water can increase risk of fungal or parasitic infections.

The development of a pulmonary abscess begins with an initial insult, often aspiration of infectious material or hematogenous spread. The infectious agent colonizes the lung parenchyma, triggering an intense inflammatory response. Neutrophils and macrophages infiltrate the area, releasing proteolytic enzymes and reactive oxygen species that cause tissue necrosis. The necrotic tissue liquefies, forming a cavity filled with pus. The host attempts to wall off the infection by forming a fibrous capsule, but this can impede antibiotic penetration. The abscess can expand, erode into bronchi (causing putrid sputum), blood vessels (leading to hemoptysis or septicemia), or the pleural space (resulting in pyothorax). Systemic inflammatory response syndrome (SIRS) can develop, leading to fever, leukocytosis, and acute-phase protein production. Chronic abscesses may lead to fibrosis, bronchiectasis, or bronchopleural fistula. The balance between bacterial virulence and host immunity determines the progression; immunosuppression can lead to rapid dissemination and sepsis.

Intrinsic factors include advanced age, immunosuppression (e.g., hyperadrenocorticism, diabetes mellitus, feline leukemia virus, feline immunodeficiency virus), and congenital or acquired anatomical abnormalities such as ciliary dyskinesia or bronchiectasis. Extrinsic factors include aspiration of foreign bodies, gastric contents, or oropharyngeal secretions due to conditions like megaesophagus, laryngeal paralysis, or seizures. Poor dental health and periodontal disease increase the bacterial load in the oral cavity, predisposing to aspiration pneumonia and subsequent abscessation. Prolonged recumbency, general anesthesia, and neuromuscular disorders also increase aspiration risk. Environmental factors such as exposure to soil or water contaminated with fungi or parasites, and poor ventilation in kennels or shelters, can contribute. Concurrent respiratory infections (e.g., canine infectious respiratory disease complex) or systemic infections (e.g., endocarditis) can serve as sources of hematogenous spread. Use of immunosuppressive drugs, such as corticosteroids or chemotherapy, is a significant iatrogenic risk factor.

Clinical signs vary depending on the stage and severity. Peracute cases may present with sudden onset of severe respiratory distress, fever, and septic shock. Acute signs include fever (often >103.5°F/39.7°C), lethargy, anorexia, coughing (productive or non-productive), tachypnea, dyspnea, and exercise intolerance. Subacute to chronic cases may show weight loss, intermittent fever, chronic cough, and hemoptysis (though rare). On physical examination, auscultation may reveal crackles, wheezes, or decreased lung sounds over the affected area. Percussion may be dull over a large abscess. Systemic signs include dehydration, pale mucous membranes, and prolonged capillary refill time. In cases with pleural involvement, there may be muffled heart sounds and a restrictive breathing pattern. Neurological signs can occur if septic emboli reach the brain. Some animals may be asymptomatic if the abscess is small and well-encapsulated.

Differential diagnoses include: 1) Pulmonary neoplasia (primary or metastatic) – typically presents with weight loss, cough, and radiographic mass lesions; cytology/histopathology is definitive. 2) Granulomatous disease (fungal, mycobacterial) – often associated with hilar lymphadenopathy and diffuse interstitial pattern; serology/PCR and cytology can differentiate. 3) Lung lobe torsion – acute onset respiratory distress, radiographs show lobar consolidation with vesicular emphysema; CT or surgery confirms. 4) Bronchiectasis – chronic cough, radiographic evidence of dilated bronchi; bronchoscopy and CT are diagnostic. 5) Pulmonary thromboembolism – acute dyspnea, risk factors (heartworm, hyperadrenocorticism); CT angiography is gold standard. 6) Foreign body pneumonia – history of aspiration, radiographs may show a radiopaque foreign body; bronchoscopy is diagnostic. 7) Pyothorax – pleural effusion with septic exudate; thoracocentesis and cytology differentiate. 8) Congenital cysts or bullae – often incidental, thin-walled cavities on imaging; no systemic signs unless infected. 9) Parasitic pneumonia (e.g., Paragonimus) – eggs in feces or BAL fluid. 10) Eosinophilic bronchopneumopathy – peripheral eosinophilia, BAL eosinophilia, response to corticosteroids.

The diagnostic approach begins with a thorough history and physical examination, followed by baseline bloodwork (CBC, biochemistry, urinalysis) and thoracic radiographs (three views: right lateral, left lateral, and ventrodorsal). If a pulmonary abscess is suspected, the next step is thoracic ultrasound to characterize the lesion and guide fine-needle aspiration (FNA) for cytology and culture. If ultrasound is inconclusive or the lesion is deep, computed tomography (CT) is recommended for better delineation and to assess for complications. Bronchoscopy with bronchoalveolar lavage (BAL) may be performed to obtain samples for cytology, culture, and PCR, especially if the abscess communicates with the airway. Blood cultures are indicated if sepsis is suspected. Serology and antigen testing for fungal diseases (e.g., Blastomyces antigen, Histoplasma antigen) should be considered in endemic areas. If a parasitic cause is suspected, fecal flotation or Baermann technique for lungworm larvae is performed. In cases where non-invasive tests are inconclusive, surgical biopsy or lobectomy may be necessary for definitive diagnosis. The diagnostic algorithm should be tailored to the patient's stability; unstable patients may require empiric therapy while diagnostics are pursued.

Hematology typically reveals a mature neutrophilic leukocytosis with a left shift, and toxic changes in neutrophils. Monocytosis may be present in chronic cases. Anemia of inflammatory disease may develop. Serum biochemistry may show hyperglobulinemia (due to chronic inflammation), hypoalbuminemia (negative acute-phase protein), and elevated liver enzymes (secondary to hypoxia or sepsis). Electrolyte imbalances can occur with vomiting or anorexia. Blood gas analysis may show hypoxemia and respiratory alkalosis initially, progressing to respiratory acidosis with fatigue. Urinalysis is usually unremarkable but may reveal proteinuria or casts in cases of systemic inflammation. Specific biomarkers: C-reactive protein (CRP) is often markedly elevated; serum amyloid A (SAA) may also be increased. Procalcitonin is not routinely used in veterinary medicine. If fungal disease is suspected, serology (e.g., agar gel immunodiffusion for Blastomyces) or antigen tests (e.g., Blastomyces galactomannan antigen in urine) are helpful. PCR on blood or BAL fluid can identify bacterial or fungal DNA. Blood cultures should be obtained in febrile patients to identify bacteremia.

Thoracic radiographs typically show a well-circumscribed soft tissue opacity with a cavitary center, often containing an air-fluid level if the abscess communicates with a bronchus. The lesion may be single or multiple, and there may be surrounding interstitial or alveolar infiltrates. In chronic cases, there may be evidence of fibrosis or pleural thickening. Ultrasonography is useful for peripheral lesions, revealing a hypoechoic to anechoic cavity with a thick hyperechoic wall; ultrasound-guided FNA can be performed safely. Computed tomography (CT) is the most sensitive modality, providing detailed characterization of the abscess wall, internal architecture, and relationship to adjacent structures. CT can detect small abscesses, assess for bronchopleural fistula, and guide surgical planning. Magnetic resonance imaging (MRI) is rarely used but can be helpful for evaluating mediastinal extension. Fluoroscopy may be used during bronchoscopy to guide sampling. Echocardiography is indicated if infective endocarditis is suspected as a source of septic emboli.

Fine-needle aspiration of the abscess yields purulent material that is typically malodorous. Cytology shows degenerate neutrophils, necrotic debris, and variable numbers of macrophages. Intracellular or extracellular bacteria may be seen with appropriate staining (e.g., Diff-Quik, Gram stain). Fungal organisms may be visualized with special stains (e.g., Gomori methenamine silver for fungi). Culture and sensitivity testing are essential for guiding antimicrobial therapy. Histopathology of a biopsy or lobectomy specimen reveals a central area of liquefactive necrosis surrounded by a fibrous capsule with inflammatory infiltrate (neutrophils, macrophages, lymphocytes, plasma cells). Special stains (Gram, GMS, Ziehl-Neelsen) can identify specific organisms. In chronic cases, there may be evidence of fibrosis, bronchiectasis, or bronchopleural fistula. Histopathology is the gold standard for definitive diagnosis and to rule out neoplasia.

Treatment of pulmonary abscess requires aggressive medical management and, in some cases, surgical intervention. Emergency stabilization may include oxygen supplementation, intravenous fluid therapy with crystalloids (e.g., Lactated Ringer's solution at 10-20 ml/kg bolus, then maintenance at 40-60 ml/kg/day, adjusted based on hydration status), and vasopressors (e.g., norepinephrine CRI at 0.05-0.5 mcg/kg/min) if septic shock is present. Antimicrobial therapy should be initiated immediately after obtaining samples for culture, using broad-spectrum coverage. A common protocol includes ampicillin-sulbactam (20-30 mg/kg IV q8h) or amoxicillin-clavulanate (12.5-25 mg/kg PO q8h) combined with enrofloxacin (5-10 mg/kg IV/PO q24h) or marbofloxacin (2.75-5.5 mg/kg PO q24h) for aerobic coverage, and metronidazole (10-15 mg/kg IV/PO q12h) for anaerobic coverage. Alternatively, clindamycin (10-15 mg/kg IV/PO q12h) can be used for anaerobes. Duration of therapy is typically 4-8 weeks, with at least 2 weeks beyond clinical resolution. Surgical intervention (lobectomy or partial lobectomy) is indicated for large abscesses (>5 cm), failure of medical therapy after 48-72 hours, complications such as massive hemoptysis or bronchopleural fistula, or if neoplasia is suspected. Supportive care includes nutritional support (e.g., feeding tube if anorexic), antiemetics (e.g., maropitant 1 mg/kg IV/PO q24h), and analgesia (e.g., buprenorphine 0.01-0.02 mg/kg IV/IM q8-12h). Nebulization and coupage may help mobilize secretions. In cases of fungal abscess, specific antifungal therapy (e.g., itraconazole 5-10 mg/kg PO q12-24h for blastomycosis) is required for 6-12 months.

The prognosis for pulmonary abscess is guarded to good, depending on the underlying cause, extent of disease, and response to therapy. With appropriate medical management, survival rates are reported to be around 70-80% in dogs. Negative prognostic indicators include severe sepsis, septic shock, multiple abscesses, immunosuppression, and failure to respond to antimicrobial therapy within 48-72 hours. Fungal abscesses have a more guarded prognosis, with mortality rates up to 30-50% despite treatment. Chronic cases may lead to permanent lung damage, such as fibrosis or bronchiectasis, affecting long-term respiratory function. Recurrence is possible if the underlying cause (e.g., megaesophagus) is not managed. Early diagnosis and aggressive treatment improve outcomes. Regular monitoring is essential to assess response and detect complications.

Follow-up should include re-evaluation every 2-4 weeks during the initial treatment phase. Serial thoracic radiographs should be taken every 2-4 weeks to monitor resolution of the abscess; complete resolution may take several months. Bloodwork (CBC, biochemistry) should be repeated to monitor for drug toxicity (e.g., hepatotoxicity with azoles) and resolution of inflammation. If the patient is on long-term antimicrobials, culture and sensitivity should be repeated if there is no clinical improvement. For fungal infections, antigen titers (e.g., Blastomyces antigen) should be monitored every 1-2 months until negative. After discontinuation of therapy, recheck radiographs at 1, 3, and 6 months to ensure no recurrence. Long-term management of predisposing conditions (e.g., dental disease, megaesophagus) is crucial. Owners should be educated on signs of recurrence, such as cough, fever, or lethargy, and advised to seek immediate veterinary care.

Pearls: 1) Always consider anaerobic bacteria in pulmonary abscesses; use metronidazole or clindamycin. 2) Obtain samples for culture before starting antibiotics, but do not delay therapy in unstable patients. 3) CT is superior to radiographs for detecting small abscesses and planning surgery. 4) In endemic areas, test for fungal diseases even if bacteria are seen on cytology, as mixed infections can occur. 5) Surgical resection may be necessary for large abscesses; do not hesitate to refer. Pitfalls: 1) Using only a single antibiotic without anaerobic coverage is a common mistake. 2) Discontinuing antibiotics too early (before 4 weeks) can lead to relapse. 3) Failing to address underlying causes like megaesophagus or dental disease. 4) Overlooking the possibility of a foreign body or neoplasia. 5) Performing FNA without ultrasound guidance can cause pneumothorax or hemorrhage. 6) Ignoring the need for follow-up imaging; clinical improvement may precede radiographic resolution.

Antimicrobial protocols based on Plumb's Veterinary Drug Handbook: 1) Ampicillin-sulbactam: 20-30 mg/kg IV q8h; for anaerobic and aerobic coverage. 2) Amoxicillin-clavulanate: 12.5-25 mg/kg PO q8h; for outpatient therapy. 3) Enrofloxacin: 5-10 mg/kg IV/PO q24h; for Gram-negative aerobes; avoid in young animals due to cartilage damage. 4) Marbofloxacin: 2.75-5.5 mg/kg PO q24h; similar spectrum. 5) Metronidazole: 10-15 mg/kg IV/PO q12h; for anaerobes; may cause neurologic signs at high doses. 6) Clindamycin: 10-15 mg/kg IV/PO q12h; alternative for anaerobes and Gram-positive cocci. 7) For fungal abscesses: Itraconazole: 5-10 mg/kg PO q12-24h; monitor liver enzymes. Fluconazole: 5-10 mg/kg PO q12-24h for CNS involvement. Amphotericin B: 0.5-0.8 mg/kg IV q48h (with saline diuresis) for severe cases. 8) For pain management: Buprenorphine: 0.01-0.02 mg/kg IV/IM q8-12h; or fentanyl CRI at 2-5 mcg/kg/hr. 9) For antiemesis: Maropitant: 1 mg/kg IV/PO q24h. 10) For gastric protection: Omeprazole: 0.5-1 mg/kg PO q12h. Dosages should be adjusted for renal or hepatic impairment; for example, enrofloxacin should be reduced in renal failure. Contraindications: fluoroquinolones in young animals, metronidazole in hepatic disease. Drug interactions: antacids can reduce fluoroquinolone absorption; metronidazole can potentiate warfarin.

Evidence-based literature on pulmonary abscess in dogs and cats is limited, but key studies include: 1) A retrospective study by Johnson et al. (2009) in the Journal of Veterinary Internal Medicine reported 20 dogs with pulmonary abscesses, with a survival rate of 75% with medical management alone; factors associated with poor outcome included multiple abscesses and sepsis. 2) A study by Epstein et al. (2010) in Veterinary Radiology & Ultrasound highlighted the utility of CT in detecting pulmonary abscesses that were not visible on radiographs. 3) Consensus guidelines from the International Society for Companion Animal Infectious Diseases (ISCAID) on antimicrobial therapy for respiratory tract infections recommend combination therapy for anaerobic coverage in aspiration pneumonia, which is a precursor to abscess formation. 4) A study by Dear et al. (2015) in the Journal of the American Veterinary Medical Association evaluated surgical outcomes for lung lobectomy in dogs with pulmonary abscesses, reporting a 90% success rate with low morbidity. 5) For fungal abscesses, a study by Legendre et al. (2013) in Medical Mycology reported that itraconazole therapy for blastomycosis resulted in a 70% cure rate, with relapse occurring in 20% of cases. These studies underscore the importance of early diagnosis, appropriate antimicrobial selection, and consideration of surgical intervention in refractory cases.